224 related articles for article (PubMed ID: 35263757)
1. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
[TBL] [Abstract][Full Text] [Related]
2. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
3. [Resiquimod (R848) has more stronger immune adjuvantivity than other tested TLR agonists].
Shen Y; Zeng M; Qiu F; Tang H
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):591-596. PubMed ID: 28502294
[TBL] [Abstract][Full Text] [Related]
4. TLR8 combined withTLR3 or TLR4 agonists enhances DC-NK driven effector Tc1 cells.
Nouri-Shirazi M; Tamjidi S; Nourishirazi E; Guinet E
Immunol Lett; 2018 Jan; 193():58-66. PubMed ID: 29103998
[TBL] [Abstract][Full Text] [Related]
5. Variable requirement of dendritic cells for recruitment of NK and T cells to different TLR agonists.
Uchida T; Scumpia PO; Murasko DM; Seki S; Woulfe S; Clare-Salzler MJ; Moldawer LL
J Immunol; 2007 Mar; 178(6):3886-92. PubMed ID: 17339488
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
8. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
9. Priming CD8+ T cells with dendritic cells matured using TLR4 and TLR7/8 ligands together enhances generation of CD8+ T cells retaining CD28.
Pufnock JS; Cigal M; Rolczynski LS; Andersen-Nissen E; Wolfl M; McElrath MJ; Greenberg PD
Blood; 2011 Jun; 117(24):6542-51. PubMed ID: 21493800
[TBL] [Abstract][Full Text] [Related]
10. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
[TBL] [Abstract][Full Text] [Related]
11. The genetic background influences the cellular and humoral immune responses to vaccines.
Zeng M; Nourishirazi E; Guinet E; Nouri-Shirazi M
Clin Exp Immunol; 2016 Nov; 186(2):190-204. PubMed ID: 27393001
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma.
Kamath AT; Sheasby CE; Tough DF
J Immunol; 2005 Jan; 174(2):767-76. PubMed ID: 15634897
[TBL] [Abstract][Full Text] [Related]
13. Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells.
Hackstein H; Hagel N; Knoche A; Kranz S; Lohmeyer J; von Wulffen W; Kershaw O; Gruber AD; Bein G; Baal N
PLoS One; 2012; 7(8):e43320. PubMed ID: 22927956
[TBL] [Abstract][Full Text] [Related]
14. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
15. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.
Kastenmüller K; Wille-Reece U; Lindsay RW; Trager LR; Darrah PA; Flynn BJ; Becker MR; Udey MC; Clausen BE; Igyarto BZ; Kaplan DH; Kastenmüller W; Germain RN; Seder RA
J Clin Invest; 2011 May; 121(5):1782-96. PubMed ID: 21540549
[TBL] [Abstract][Full Text] [Related]
16. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
17. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways.
Sawaki J; Tsutsui H; Hayashi N; Yasuda K; Akira S; Tanizawa T; Nakanishi K
Int Immunol; 2007 Mar; 19(3):311-20. PubMed ID: 17289654
[TBL] [Abstract][Full Text] [Related]
18. Immunoadjuvant effects of polyadenylic:polyuridylic acids through TLR3 and TLR7.
Sugiyama T; Hoshino K; Saito M; Yano T; Sasaki I; Yamazaki C; Akira S; Kaisho T
Int Immunol; 2008 Jan; 20(1):1-9. PubMed ID: 17981792
[TBL] [Abstract][Full Text] [Related]
19. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
[TBL] [Abstract][Full Text] [Related]
20. High-avidity antitumor T-cell generation by toll receptor 8-primed, myeloid- derived dendritic cells is mediated by IL-12 production.
Xu S; Koldovsky U; Xu M; Wang D; Fitzpatrick E; Son G; Koski G; Czerniecki BJ
Surgery; 2006 Aug; 140(2):170-8. PubMed ID: 16904966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
